Trading Signals: BLUE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. May. 13, 2022)(BLUEBIRD BIO INC)
| BLUE latest price $125.0700 (4.22%) ($122.3600 - $127.9800) on Tue. Aug. 25, 2015. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 2.68% (three month average) | | RSI | 50 | | Latest Price | $125.0700(4.22%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | BLUE declines -0.7% a day on average for past five trading days. | | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support BLUE advance at 0% a week (0% probability)
XBI(63%) IBB(59%) IWO(47%) IWM(42%) XLV(39%) | | Factors Impacting BLUE price | BLUE will decline at least -1.34% in a week (0% probabilities).
VIXM(-20%) TLT(-12%) SHY(-8%) UUP(-6%) TAN(-2%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.34% (StdDev 2.68%) | | Hourly BBV | 0 () | | Intraday Trend | -0.5% | | | | | |
|
| 5 Day Moving Average | $123.43(1.33%) | | 10 Day Moving Average | $127.05(-1.56%) | | 20 Day Moving Average | $0(0%) | | To recent high | -10.2% | | To recent low | 4.2% | | Market Cap | $8.279b | | | | | | |
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA. |